Covington Represents Petrichor in Financing with VERO Biotech

WASHINGTON—Covington advised Petrichor, a leading healthcare-dedicated growth capital provider, in its $30 million financing of VERO Biotech Inc., a commercial-stage healthcare business dedicated to neonatal intensive care and the acute care hospital community.

The proceeds will support further development and commercialization of VERO Biotech's GENOSYL Delivery System (DS), a tankless inhaled nitric oxide (iNO) delivery system. The third generation of the GENOSYL DS was recently approved by the FDA and represents a breakthrough in iNO technology benefitting both providers and patients.

The Covington team included Brent Little and Brendon Francis (Finance), Joseph Gangitano (Corporate), Martin Beeler (Bankruptcy), Amy Leiser (Medical Device Regulatory), and Anna Hevia (Sanctions).